Trial · NCT07891247
Complementary Exercise-Based Therapy for Obstructive Sleep Apnea
NCT07891247, Not applicable, Completed, bioROne
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Complementary Exercise-Based Therapy for Obstructive Sleep Apnea. Trials, record NCT07891247. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891247
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Complementary Exercise-Based Therapy for Obstructive Sleep Apnea
- NCT number
- NCT07891247
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 24 participants, actual
- Lead sponsor
- bioROne
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Multimodal Exercise, Respiratory and Cervical-Postural Rehabilitation Program, Continuous Positive Airway Pressure (CPAP)
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Residual Apnea-Hypopnea Index (AHI) During CPAP Therapy | Baseline and Day 90 | The residual apnea-hypopnea index (AHI) is the number of apneas and hypopneas per hour of \[recording time / estimated sleep time\], measured by overnight cardiorespiratory polygraphy without electroencephalography, performed while the participant was using their home CPAP device. Events are scored according to American Academy of Sleep Medicine (AASM) criteria: apnea is defined as a reduction in airflow of at least 90% lasting at least 10 seconds, and hypopnea as a reduction in airflow of at least 30% lasting at least 10 seconds, associated with an oxygen desaturation of at least \[3% / 4%\]. AHI isexpressed in events per hour. Change is calculated as the Day 90 value minus the baseline value; a negative change indicates improvement. |
| Secondary | Percentage of Participants With Improvement in Residual Apnea-Hypopnea Index (AHI) Severity Category | Baseline and Day 90 | Residual AHI, measured as described for Outcome Measure 1, is classified into four categories: normal (\<5 events/hour), mild (5 to \<15 events/hour), moderate (15 to \<30 events/hour) and severe (≥30 events/hour). Improvement is defined as a shift to a lower category at Day 90 compared with baseline. |
| Secondary | Percentage of Participants With at Least 50% Reduction in Residual Apnea-HypopneaIndex (AHI) | Baseline and Day 90 | Percentage of participants whose residual AHI at Day 90 is reduced by at least 50% compared with baseline. Residual AHI is measured as described for Outcome Measure 1. |
| Secondary | Change in Oxygen Desaturation Index (ODI) | Baseline and Day 90 | The oxygen desaturation index (ODI) is the number of oxygen desaturation episodes of at least \[3% / 4%\] from baseline saturation per hour of \[recording time / estimated sleep time\], measured by the pulse oximetry channel of the overnight cardiorespiratory polygraphy described for Outcome Measure 1. ODI is expressed in events per hour. Change is calculated as the Day 90 value minus the baseline value; a negative change indicates improvement. |
| Secondary | Change in Mean Nocturnal Oxygen Saturation (SpO2) | Baseline and Day 90 | Mean peripheral oxygen saturation (SpO2) over the recording period, measured by the pulse oximetry channel of the overnight cardiorespiratory polygraphy describedfor Outcome Measure 1, expressed as a percentage (%). Change is calculated as the Day 90value minus the baseline value; a positive change indicates improvement. |
| Secondary | Change in Minimum Nocturnal Oxygen Saturation (SpO2) | Baseline and Day 90 | The lowest peripheral oxygen saturation (SpO2) recorded during the night bythe pulse oximetry channel of the overnight cardiorespiratory polygraphy described for Outcome Measure 1, expressed as a percentage (%). Change is calculated as the Day 90 value minus the baseline value; a positive change indicates improvement. |
| Secondary | Change in Percentage of Recording Time With Oxygen Saturation Below 90% (T90) | Baseline and Day 90 | T90 is the percentage of total recording time spent with peripheral oxygensaturation (SpO2) below 90%, measured by the pulse oximetry channel of the overnight cardiorespiratory polygraphy described for Outcome Measure 1. Expressed as a percentage ofrecording time (%). Change is calculated as the Day 90 value minus the baseline value; anegative change indicates improvement. |
| Secondary | Change in Number of Oxygen Desaturations Below 90% | Baseline and Day 90 | The number of desaturation episodes during which peripheral oxygen saturation (SpO2) fell below 90%, counted over the entire overnight cardiorespiratory polygraphyrecording described for Outcome Measure 1. Expressed as the number of episodes per night. Change is calculated as the Day 90 value minus the baseline value; a negative changeindicates improvement. |
| Secondary | Change in Daytime Sleepiness Assessed by the Epworth Sleepiness Scale (ESS) | Baseline and Day 90 | The Epworth Sleepiness Scale (ESS) is an 8-item self-administered questionnaire assessing the likelihood of dozing off in 8 common daily situations. Each item is rated from 0 (would never doze) to 3 (high chance of dozing). The total score ranges from0 to 24. Higher scores indicate greater daytime sleepiness (worse outcome). A negative change from baseline indicates improvement. |
| Secondary | Change in Resting Systolic Blood Pressure | Baseline and Day 90 | Systolic blood pressure measured at rest at the study visit, expressed in millimeters of mercury (mmHg). Change is calculated as the Day 90 value minus the baseline value. |
1 to 10 of 27Source ClinicalTrials.gov
See all 27 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891247
GET https://conductscience.org/api/trials/v1/NCT07891247/registered?page=2